R1 RCM (NASDAQ:RCM) Releases Earnings Results, Misses Estimates By $0.03 EPS

R1 RCM (NASDAQ:RCM) issued its earnings results on Wednesday. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03), Briefing.com reports. R1 RCM had a return on equity of 0.12% and a net margin of 0.15%. The firm had revenue of $603.90 million during the quarter, compared to the consensus estimate of $612.88 million. The company’s quarterly revenue was up 10.7% on a year-over-year basis. R1 RCM updated its FY 2024 guidance to EPS.

R1 RCM Stock Performance

R1 RCM stock traded down $0.57 during trading hours on Thursday, reaching $12.27. The company had a trading volume of 8,955,608 shares, compared to its average volume of 3,533,999. R1 RCM has a 12-month low of $8.87 and a 12-month high of $18.70. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.83 and a quick ratio of 1.83. The company has a 50-day moving average price of $12.88 and a 200 day moving average price of $11.46.

Insider Transactions at R1 RCM

In other R1 RCM news, President John M. Sparby sold 10,046 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the transaction, the president now owns 265,986 shares in the company, valued at $3,811,579.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 36.80% of the company’s stock.

Wall Street Analyst Weigh In

RCM has been the topic of a number of analyst reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of R1 RCM in a report on Monday, February 26th. Truist Financial reaffirmed a “hold” rating and issued a $16.00 target price on shares of R1 RCM in a report on Monday, April 1st. SVB Leerink started coverage on R1 RCM in a report on Monday, February 26th. They set an “outperform” rating and a $14.00 price target on the stock. KeyCorp reiterated a “sector weight” rating on shares of R1 RCM in a research note on Wednesday, April 10th. Finally, Morgan Stanley restated an “overweight” rating and set a $17.00 price objective on shares of R1 RCM in a report on Tuesday, March 26th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.71.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.